N-Acetyl-L-aspartic acid
(Synonyms: N-乙酰-L-天门冬氨酸) 目录号 : GC33612
An acetylated form of L-aspartic acid
Cas No.:997-55-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
N-Acetyl-L-aspartic acid is an acetylated form of L-aspartic acid.1 It is formed from L-aspartate and acetyl-CoA by L-aspartate N-acetyltransferase (Asp-NAT) in neuronal mitochondria.2 N-Acetyl-L-aspartic acid is hydrolyzed to L-aspartate and acetate by aspartoacylase (ASPA), which is expressed by oligodendrocytes. N-Acetyl-L-aspartic acid levels are increased in the brain of patients with Canavan disease, an autosomal recessive disorder caused by loss-of-function ASPA mutations and characterized by cognitive and motor impairments.3,2,1
1.Baslow, M.H.A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-?-aspartic acid and N-acetyl-?-histidine, in the vertebrate nervous systemJ. Neurochem.68(4)1335-1344(1997) 2.Madhavarao, C.N., Arun, P., Moffett, J.R., et al.Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's diseaseProc. Natl. Acad. Sci. USA102(14)5221-5226(2004) 3.Bannerman, P., Guo, F., Chechneva, O., et al.Brain Nat8l knockdown suppresses spongiform leukodystrophy in an aspartoacylase-deficient Canavan disease mouse modelMol. Ther.26(3)793-800(2018)
| Cas No. | 997-55-7 | SDF | |
| 别名 | N-乙酰-L-天门冬氨酸 | ||
| Canonical SMILES | O=C(O)C[C@@H](C(O)=O)NC(C)=O | ||
| 分子式 | C6H9NO5 | 分子量 | 175.14 |
| 溶解度 | H2O : 62.5 mg/mL (356.86 mM; Need ultrasonic); DMSO : 5 mg/mL (28.55 mM; ultrasonic and warming and heat to 80°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7097 mL | 28.5486 mL | 57.0972 mL |
| 5 mM | 1.1419 mL | 5.7097 mL | 11.4194 mL |
| 10 mM | 0.571 mL | 2.8549 mL | 5.7097 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet